Risperdal Trial Reveals Johnson & Johnson Hid Gynecomastia Side Effect

Testimony from a Johnson & Johnson biochemist revealed the company hid study results linking its antipsychotic drug Risperdal to dangerous hormonal levels from the U.S. Food and Drug Administration.

A recent article in New Brunswick Today made testimony from the February trial of Austin Pledger public. A jury awarded the Alabama man $2.5 million for side effects he suffered from taking Risperdal (risperidone) as a child.

Janssen Pharmaceuticals, a subsidiary of J&J, funded the 2003 study which concluded it found no link between elevated prolactin levels and long-term risperidone treatment.

Visit Original Source